Hydatidiform mole (often referred to as molar pregnancy) is the most common disorder in a category of pathologies known as Gestational Trophoblastic Diseases that are associated with abnormal fertilization in pregnancy. Current practices in screening and monitoring during early pregnancy allow for better identification of hydatidiform mole, sometimes prior to the onset of significant symptoms.Once a diagnosis is established, a thorough physical examination and laboratory testing are necessary. Initial treatment includes uterine evacuation. Serial monitoring of serum human chorionic gonadotropin levels is warranted until levels become nondetectable and continues for another 6 months. Reliable contraception is necessary until it has been determined that no trophoblastic tissue persists.Pregnancy is usually a joyful time, with maternal attachment to the developing fetus beginning early in the pregnancy. The woman who experiences hydatiform mole, however, must face the inability to maintain this pregnancy, the possible health consequences of the mole, and then be allowed the time to grieve. Nurses can be the first-line in providing compassionate, empathetic care for women in these circumstances.

Download full-text PDF

Source
http://dx.doi.org/10.1097/NMC.0b013e31823853c4DOI Listing

Publication Analysis

Top Keywords

hydatidiform mole
12
early pregnancy
8
mole
5
pregnancy
5
understanding hydatidiform
4
mole hydatidiform
4
mole referred
4
referred molar
4
molar pregnancy
4
pregnancy common
4

Similar Publications

Serum hCG levels in the prediction of molar pregnancy below 11 weeks of gestational age.

Rev Assoc Med Bras (1992)

December 2024

Universidade Federal de São Paulo, Escola Paulista de Medicina, Department of Obstetrics - São Paulo (SP), Brazil.

Objective: The aim of this study was to evaluate the serum hCG level in the differential diagnosis between non-molar miscarriage and complete hydatidiform mole in<11 weeks gestation.

Methods: This was a retrospective collaborative cohort study. This study included women with gestational age<11 weeks, with ultrasound evidence of failed pregnancy and available serum hCG pre-uterine evacuation, divided into two groups: the non-molar miscarriage group and the complete hydatidiform mole group.

View Article and Find Full Text PDF

Objectives: To audit outcomes of patients registered in the Queensland Trophoblast Centre (QTC) database who develop resistance to primary chemotherapy. To determine any risk factors that may predict first-line chemotherapy resistance in patients diagnosed with gestational trophoblastic neoplasia (GTN).

Methods: Patients within the QTC who were diagnosed with GTN between January 2012 and December 2020 were reviewed.

View Article and Find Full Text PDF

Objective: To evaluate the clinical efficacy of hysteroscopy in the treatment of molar pregnancy and postoperative residual tissue.

Methods: This retrospective study involved 68 patients who underwent treatment for molar pregnancy in Shanxi Children's Hospital Shanxi Maternal and Child Health Hospital from April 2020 to May 2022. Based on intervention methods, patients were divided into a conventional group (n=33) and a hysteroscopy group (n=35).

View Article and Find Full Text PDF

Gestational trophoblastic neoplasm: Patient outcomes and clinical pearls from a multidisciplinary referral center.

Gynecol Oncol

December 2024

Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States; Department of Medicine, Weill Cornell Medical College, New York, NY, United States.

Objectives: To describe clinical outcomes and pearls for patients with gestational trophoblastic neoplasm (GTN).

Methods: Patients with GTN treated at a referral center from 1/2006 to 12/2022 were included. Clinical characteristics, World Health Organization risk score (low-risk 0-6, high-risk ≥7), and treatments/outcomes were evaluated using summary statistics, stratified by initial treatment at a referral center versus locally.

View Article and Find Full Text PDF

Vaginal metastasis in gestational trophoblastic neoplasia: Experience from Sheffield trophoblastic disease Centre and recommendations for management.

Eur J Obstet Gynecol Reprod Biol

November 2024

Sheffield Trophoblastic Disease Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

Introduction: Gestational trophoblastic neoplasia (GTN) is rare in the UK, with an estimated incidence of one in 50,000 live births. Cases of vaginal metastasis are even rarer, with only eight case series reporting 187 cases over the past 40 years. Management recommendations in the literature are scarce despite the potential risk of massive, potentially life-threatening vaginal haemorrhage.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!